PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction [Philadelphia]

June 27, 2019



Loews Philadelphia Hotel
1200 Market St.
Philadelphia, PA 19107

Thursday, June 27, 2019
6:00 - 6:30 pm - Registration & Dinner
6:30 - 8:30 pm - Program

This symposium reviews current cardiovascular outcomes data for PCSK9 inhibitors, how to integrate non-statin lipid-lowering therapies and current cholesterol guidelines for the management of high CV-risk patients, and strategies for gaining access to PCSK9 inhibitors for high CV risk patients that need them. 

In addition, attendees will have an opportunity to develop a treatment plan for real-world patients and compare and discuss their strategies with the faculty panel. Attendees are also encouraged to bring or submit difficult cases and questions to challenge the faculty in the “Stump the Faculty” segment.

Intended Learners
This CME initiative will target Lipid Specialists, Cardiologists, Endocrinologists, Primary Care Providers (MDs/DOs), nurse practitioners (NPs), physician assistants (PAs), and other healthcare providers who practice in a primary care setting. 

Learning Objectives

  1. Assess current cardiovascular outcomes data for PCSK9 inhibitors in patients at increased risk for CV events
  2. Integrate PCSK9 inhibitors in the management of real-world patients at high CV risk requiring additional LDL-C reduction 
  3. Formulate strategies to improve patient access to PCSK9 inhibitors for those who require further CV risk reduction


Privacy Statement: For online registration, we take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline. In order to use this website, a user must first complete the registration form. During registration, a user is required to give certain information (such as name, email/mailing address and payment information). This information is confidential and will only be used to contact you regarding your registration.

Supporter Acknowledgment Statement  
This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.


 Thursday, June 27, 2019

6:00-6:30pm Registration & Complimentary Dinner
6:30-6:35pm Welcome & Pre-activity Assessment

PCSK9 Inhibitors: A New Option for Reducing Cardiovascular Events in High-Risk Patients?

6:50-7:50pm Challenging Cases: What would you do?
Real-world patient cases for group case workshop – develop and discuss treatment plan with faculty panel
7:50-8:20pm Stump the Faculty: Controversies and Challenges in Lipid Management
Bring or submit your difficult cases and questions to challenge the faculty
8:20-8:30pm Post-activity Assessment & Adjourn 


SofferDaniel Soffer, MD, FNLA, FACP
Clinical Associate Professor of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Faculty Bio
Dr. Soffer is a Clinical Associate Professor of Medicine in the Division of General Internal Medicine and Division of Translational Medicine and Human Genetics at Perelman School of Medicine of the University of Pennsylvania. His clinical focus is Preventive Cardiovascular Medicine and General Internal Medicine. He is a Diplomate of the American Board of Clinical Lipidology. Dr. Soffer is President (2018/2019) of the Northeast Chapter of the National Lipid Association (NLA) and the Director of the Philadelphia Lipid and Atherosclerosis Club (PLAC). He is the co-Editor of LipidSpin and co-Director of the Foundations of Lipidology course for the NLA. He earned a BA from the University of Pennsylvania and also graduated from the University of Pennsylvania Medical School. In addition to clinical medicine and teaching, he also participates as an investigator in ongoing clinical research with lipid-modifying pharmacotherapies. His internship and residency were completed at the Hospital of the University of Pennsylvania. He has been a full-time clinician at his suburban Medical practice in Media PA, splitting his time with Preventive Cardiology since 2006. 

Disclosure - Dr. Daniel Soffer has served on Advisory Boards for Medicure, Akcea and Regeneron. He has served as a Consultant for Amgen and on a Speakers Bureau for Akcea.

JacobyDouglas S. Jacoby, MD
Director, Penn Cardiology Preventative Care
Medical Director, Penn Presbyterian Heart and Vascular Pavilion
Associate Professor of Clinical Medicine
Penn Medicine
Philadelphia, PA

Faculty Bio
Douglas S. Jacoby, MD, FACC, FNLA is an Associate Professor of Clinical Medicine at the Perelman School of Medicine at the University of Pennsylvania. He serves as the medical director of the Penn Medicine Center for Preventive Cardiology and Lipid Management, which focuses on assessing and reducing all aspects of cardiovascular risk. Dr. Jacoby received both his undergraduate and medical degrees from Harvard University, and completed residency and a cardiology fellowship at the University of Pennsylvania.  He practices both as a cardiologist and lipidologist.  In primary prevention, his clinical interests involve more accurately assessing cardiovascular risk, especially in patients with a family history of heart disease or unique risk factors such as radiation therapy. In both primary and secondary prevention, Dr. Jacoby focuses on reducing all modifiable risk factors of heart attacks and strokes, including cholesterol disorders, hypertension and diabetes.   Dr. Jacoby works with his patients to preserve their long-term health.  

Disclosure - Dr. Douglas Jacoby has served on a Lipid Expert Advisory Panel for Regeneron and conducted education on advanced lipid testing for Quest.

UnderbergJames A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA 
Preventive CV Medicine, Lipidology and Hypertension 
Clinical Assistant Professor of Medicine 
NYU Medical School & NYU Center for CV Prevention 
Director, Bellevue Hospital Lipid Clinic 
President, Northeast Chapter National Lipid Association
NYU Langone Medical Center LLC
New York, NY

Faculty Bio 
Dr. Underberg is a Clinical Lipidologist. He is a Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease. He is also the Director of the Bellevue Hospital Lipid Clinic. Dr. Underberg holds joint appointments in the divisions of general internal medicine and endocrinology at NYU. Dr. Underberg is a Diplomate of the American Board of Clinical Lipidology and President of the National Lipid Association. He is a Fellow of the National Lipid Association, A Fellow of the American College of Physicians, A Fellow of the NY Academy of Medicine and Vice President of the American Board of Clinical Lipidology. He serves on the editorial board of the Journal of Clinical Lipidology and is a board member of the National Lipid Association, the Foundation of the National Lipid Association, The American Society of Preventive Cardiology and the American Board of Clinical Lipidology. Dr. Underberg also serves on the scientific advisory board of the FH Foundation. Dr. Underberg’s Clinical Interests focus on the clinical management of patients with lipids and lipoprotein disorders and cardiovascular disease prevention. He maintains an active clinical research program in these areas and has authored numerous articles and book chapters in the field of Clinical Lipidology.

Disclosure - Dr. Underberg has served on a Speakers Bureau for Amgen, Sanofi, Regeneron, Amarin, Akacea and Alexion. He has served as a Consultant for Amgen and Ambry and performed contracted research for Aegerion.

Other Contributor/Planner Disclosures
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose. 

CME Information

Accreditation Statement
Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Horizon CME designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC CreditABIM MOC Statement 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. 

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

How To Claim Credit

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the pre-test, post-test and activity evaluation

Statement of credit will be available to print from your user history page.